COVID Update: Masks are still required in health care settings, even if you’re fully vaccinated. Also, Scripps does not provide COVID-19 tests for asymptomatic patients. See FAQs.
Investigational cell therapy to prevent rejection of a transplanted kidney
Christopher Marsh, M.D.
This is a randomized trial to evaluate the safety and effectiveness of a investigational stem-cell based therapy compared to standard anti-rejection treatment in living donor renal transplant patients. All surgery, procedures and treatments will take place at Scripps Clinic/ Green Hospital Torrey Pines.
• Be at least 18 years old
• Be clinically indicated for a kidney transplant
• Have identified a suitable living kidney donor between ages 18-60
• Must qualify for kidney transplant through our Solid Organ Transplant Department
• Meet additional criteria
Patients must not:
• Have a BMI >35
• Be a biologically unrelated female donor to male recipient
• Have had a previous transplant
FREEDOM-1 is exploring the use an investigational cell therapy comprised of stem cells, which are immature cells, obtained from a living donor to prevent rejection after a kidney transplant. Patients will be randomized to receive the investigational therapy or standard anti-rejection treatment. Total study duration is expected to be about 5 years. Travel reimbursement is provided.
Search for NCT 03995901 at www.clinicaltrials.gov for more information